Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kyverna Therapeutics

2.10
-0.0400-1.87%
Post-market: 2.100.00000.00%16:05 EDT
Volume:153.95K
Turnover:325.55K
Market Cap:90.76M
PE:-0.63
High:2.22
Open:2.11
Low:2.07
Close:2.14
Loading ...

BRIEF-Kyverna Therapeutics Files For Offering Of Up To $50 Mln Common Stock From Time To Time - SEC Filing

Reuters
·
16 Apr

Kyverna Therapeutics Files for Offering of up to $50 Mln Common Stock From Time to Time - SEC Filing

THOMSON REUTERS
·
16 Apr

Kyverna Therapeutics Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
03 Apr

Kyverna Therapeutics price target lowered to $4 from $6 at H.C. Wainwright

TIPRANKS
·
03 Apr

Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX) and Boundless Bio Inc. (BOLD)

TIPRANKS
·
03 Apr

Kyverna Therapeutics Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
01 Apr

Kyverna Therapeutics Inc : Morgan Stanley Cuts Target Price to $20 From $40

THOMSON REUTERS
·
01 Apr

Kyverna Therapeutics price target lowered to $12 from $13 at UBS

TIPRANKS
·
29 Mar

Kyverna Therapeutics Advances CAR T-Cell Therapy Trials

TIPRANKS
·
29 Mar

Kyverna Therapeutics Inc Strong Balance Sheet Extends Cash Runway Into 2027 Through Key Clinical And Regulatory Catalysts

Reuters
·
28 Mar

Kyverna Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Mar

BRIEF-Kyverna Therapeutics Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing

Reuters
·
28 Mar

Kyverna Therapeutics files $250M mixed securities shelf

TIPRANKS
·
28 Mar

Kyverna Therapeutics Inc Files for Mixed Shelf of up to $250 Mln - SEC Filing

THOMSON REUTERS
·
28 Mar

Kyverna Therapeutics Inc: Strong Balance Sheet Extends Cash Runway Into 2027 Through Key Clinical and Regulatory Catalysts

THOMSON REUTERS
·
28 Mar

Kyverna Therapeutics sees cash and securities sufficient into 2027

TIPRANKS
·
28 Mar

Kyverna Therapeutics FY24 EPS ($3.33) Up From ($89.61) YoY.

Benzinga
·
28 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Mar

Kyverna Therapeutics Inc expected to post a loss of 84 cents a share - Earnings Preview

Reuters
·
22 Mar

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

PR Newswire
·
04 Mar